These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33581579)

  • 1. PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression.
    Wu L; Cai S; Deng Y; Zhang Z; Zhou X; Su Y; Xu D
    Int Immunopharmacol; 2021 May; 94():107443. PubMed ID: 33581579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
    Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
    Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway.
    Tsai TF; Lin JF; Lin YC; Chou KY; Chen HE; Ho CY; Chen PC; Hwang TI
    Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31341011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
    Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
    Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer.
    Zhang C; Li Z; Xu L; Che X; Wen T; Fan Y; Li C; Wang S; Cheng Y; Wang X; Qu X; Liu Y
    BMC Cancer; 2018 Apr; 18(1):462. PubMed ID: 29690901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DJ-1 is involved in the multidrug resistance of SGC7901 gastric cancer cells through PTEN/PI3K/Akt/Nrf2 pathway.
    Qiu L; Ma Z; Li X; Deng Y; Duan G; Zhao LE; Xu X; Xiao L; Liu H; Zhu Z; Chen H
    Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(11):1202-1214. PubMed ID: 33079995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma.
    Zhang ZS; Yang RH; Yao X; Cheng YY; Shi HX; Yao CY; Gao ZX; Qi DF; Zhang WK; Dou YY; Guo J; Hu MW; Zhao H; Fang D
    Cell Biol Int; 2021 Dec; 45(12):2521-2533. PubMed ID: 34486197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
    Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
    J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells.
    Yan F; Pang J; Peng Y; Molina JR; Yang P; Liu S
    PLoS One; 2016; 11(9):e0162925. PubMed ID: 27610620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-873/PD-L1 axis regulates the stemness of breast cancer cells.
    Gao L; Guo Q; Li X; Yang X; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Xi T; Zheng L
    EBioMedicine; 2019 Mar; 41():395-407. PubMed ID: 30803931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 Status in Gastric Cancers, Association with the Transcriptional, Growth Factors, AKT/mTOR Components Change, and Autophagy Initiation.
    Spirina L; Avgustinovich A; Afanas'ev S; Volkov M; Dobrodeev A; Cheremisina O; Kostromitsky D
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poncirin downregulates ATP-binding cassette transporters to enhance cisplatin sensitivity in cisplatin-resistant osteosarcoma cells.
    Zhao L; Zhang W; Zhang F
    Phytother Res; 2021 Jan; 35(1):278-288. PubMed ID: 32779800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
    Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
    Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
    Dastmalchi N; Hosseinpourfeizi MA; Khojasteh SMB; Baradaran B; Safaralizadeh R
    Life Sci; 2020 Oct; 259():118239. PubMed ID: 32784058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-κB pathway.
    Sui H; Pan SF; Feng Y; Jin BH; Liu X; Zhou LH; Hou FG; Wang WH; Fu XL; Han ZF; Ren JL; Shi XL; Zhu HR; Li Q
    BMC Complement Altern Med; 2014 Aug; 14():279. PubMed ID: 25085593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
    Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
    Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of integrin-linked kinase in multi-drug resistance of human gastric carcinoma SGC7901/DDP cells.
    Song W; Jiang R; Zhao CM
    Asian Pac J Cancer Prev; 2012; 13(11):5619-25. PubMed ID: 23317227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.
    Zhang X; Zeng Y; Qu Q; Zhu J; Liu Z; Ning W; Zeng H; Zhang N; Du W; Chen C; Huang JA
    Int J Clin Oncol; 2017 Dec; 22(6):1026-1033. PubMed ID: 28748356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.